Modeling of corticosteroid effects on hepatic low-density lipoprotein receptors and plasma lipid dynamics in rats

Pharmaceutical Research

Volumn 25, Issue 4, 2008, Pages 769-780

  Hazra, Anasuya ^a,b   Pyszczynski, Nancy A ^a   DuBois, Debra C ^a   Almon, Richard R ^a   Jusko, William J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b PFIZER INC   (United States)

Author keywords

Cholesterol; Corticosteroids; Glucocorticoid receptors; LDL receptors; Lipids; Pharmacodynamics

Indexed keywords

CORTICOSTEROID; GLUCOCORTICOID RECEPTOR; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; METHYLPREDNISOLONE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CIRCADIAN RHYTHM; CONTROLLED STUDY; DOWN REGULATION; DRUG HALF LIFE; DRUG MECHANISM; LIPID BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CIRCADIAN RHYTHM; GLUCOCORTICOIDS; INJECTIONS, INTRAMUSCULAR; LIPID METABOLISM; LIPIDS; LIVER; MALE; METHYLPREDNISOLONE HEMISUCCINATE; MODELS, BIOLOGICAL; RATS; RATS, WISTAR; RECEPTORS, GLUCOCORTICOID; RECEPTORS, LDL; RNA, MESSENGER; TRIGLYCERIDES;

EID: 43349089684     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-007-9371-8     Document Type: Article

References (42)

1. H. Schacke, W. D. Docke, and K. Asadullah. Mechanisms involved in the side effects of glucocorticoids. Pharmacol. Ther. 96:23-43 (2002).
2. D. Adlersberg, L. Schaefer, and S. R. Drachman. Development of hypercholesteremia during cortisone and ACTH therapy. JAMA 144:909-914 (1950).
3. R. L. Blum. Computer-assisted design of studies using routine clinical data. Analyzing the association of prednisone and cholesterol. Ann Int Med 104:858-868 (1986).
4. J. D. Bagdade, E. Yee, J. Albers, and O. J. Pykalisto. Glucocorticoids and triglyceride transport: effects on triglyceride secretion rates, lipoprotein lipase, and plasma lipoproteins in the rat. Metab. Clin. Exp. 25:533-542 (1976).
5. D. M. Becker, M. Markakis, M. Sension, S. Vitalis, K. Baughman, R. Swank, P. O. Kwiterovich, T. A. Pearson, S. C. Achuff, and W. A. Baumgartner. Prevalence of hyperlipidemia in heart transplant recipients. Transplantation 44:323-325 (1987).
6. B. Staels, A. van Tol, L. Chan, G. Verhoeven, and J. Auwerx. Variable effects of different corticosteroids on plasma lipids, apolipoproteins, and hepatic apolipoprotein mRNA levels in rats. Arterioscler. Thromb. 11:760-769 (1991).
7. D. W. Bilheimer. Regulation of LDL receptors in vivo. Agents Actions Suppl 16:191-203 (1984).
8. A. M. Salter, S. C. Fisher, and D. N. Brindley. Binding of low-density lipoprotein to monolayer cultures of rat hepatocytes is increased by insulin and decreased by dexamethasone. FEBS Lett. 220:159-162 (1987).
9. M. S. Brown and J. L. Goldstein. A receptor-mediated pathway for cholesterol homeostasis. Science 232:34-47 (1986).
10. O. Al Rayyes, A. Wallmark, and C. H. Floren. Additive inhibitory effect of hydrocortisone and cyclosporine on low-density lipoprotein receptor activity in cultured HepG2 cells. Hepatology 26:967-971 (1997).
11. R. R. Almon, J. Chen, G. Snyder, D. C. Dubois, W. J. Jusko, and E. P. Hoffman. In vivo multi-tissue corticosteroid microarray time series available online at Public Expression Profile Resource (PEPR). Pharmacogenomics 4:791-799 (2003).
12. Y. N. Sun, D. C. DuBois, R. R. Almon, and W. J. Jusko. Fourth-generation model for corticosteroid pharmacodynamics: a model for methylprednisolone effects on receptor/gene-mediated glucocorticoid receptor down-regulation and tyrosine aminotransferase induction in rat liver. J. Pharmacokinet. Biopharm. 26:289-317 (1998).
13. Y. N. Sun, L. I. McKay, D. C. DuBois, W. J. Jusko, and R. R. Almon. Pharmacokinetic/pharmacodynamic models for corticosteroid receptor down-regulation and glutamine synthetase induction in rat skeletal muscle by a receptor/gene-mediated mechanism. J. Pharmacol. Exp. Ther. 288:720-728 (1999).
14. D. B. Haughey and W. J. Jusko. Analysis of methylprednisolone, methylprednisone and corticosterone for assessment of methylprednisolone disposition in the rat. J. Chromatogr. 430:241-248 (1988).
15. D. C. DuBois, R. R. Almon, and W. J. Jusko. Molar quantification of specific messenger ribonucleic acid expression in northern hybridization using cRNA standards. Anal. Biochem. 210:140-144 (1993).
16. A. Hazra, W. J. Jusko, R. R. Almon, and D. C. DuBois. Pharmacodynamics of circadian rhythm of corticosterone effects on tyrosine aminotransferase in normal rats. AAPS J 6: Abstract T3355 (2005).
17. Z. Yao, D. C. Dubois, R. R. Almon, and W. J. Jusko. Modeling circadian rhythms of glucocorticoid receptor and glutamine synthetase expression in rat skeletal muscle. Pharm. Res. 23:670-679 (2006).
18. A. Hazra, N. A. Pyszczynski, D. C. Dubois, R. R. Almon, and W. J. Jusko. Pharmacokinetics of methylprednisolone after intravenous and intramuscular administration in rats. Biopharm. Drug Dispos. 28:263-273 (2007).
19. M. J. Schaaf and J. A. Cidlowski. Molecular mechanisms of glucocorticoid action and resistance. J. Steroid Biochem. Mol. Biol. 83:37-48 (2002).
20. R. J. Hache, R. Tse, T. Reich, J. G. Savory, and Y. A. Lefebvre. Nucleocytoplasmic trafficking of steroid-free glucocorticoid receptor. J. Biol. Chem. 274:1432-1439 (1999).
21. H. Htun, J. Barsony, I. Renyi, D. L. Gould, and G. L. Hager. Visualization of glucocorticoid receptor translocation and intranuclear organization in living cells with a green fluorescent protein chimera. Proc. Natl. Acad. Sci. U. S. A. 93:4845-4850 (1996).
22. R. H. Oakley and J. A. Cidlowski. Homologous down regulation of the glucocorticoid receptor: the molecular machinery. Crit. Rev. Eukaryot. Gene Expr. 3:63-88 (1993).
23. M. Beato, G. Chalepakis, M. Schauer, and E. P. Slater. DNA regulatory elements for steroid hormones. J. Steroid Biochem. 32:737-747 (1989).
24. K. L. Burnstein, C. M. Jewell, and J. A. Cidlowski. Human glucocorticoid receptor cDNA contains sequences sufficient for receptor down-regulation. J. Biol. Chem. 265:7284-7291 (1990).
25. A. Hazra, D.C. Dubois, R.R. Almon, and W.J. Jusko. Assessing the dynamics of nuclear glucocoticoid-receptor complex: Adding flexibility to gene expression modeling. J. Pharmacokinet. Pharmacodyn. 34:333-354 (2007).
26. A.-N. Kong, G. L. Jungbluth, M. T. Pasko, T. R. Beam, and W. J. Jusko. Pharmacokinetics of methylprednisolone sodium succinate and methylprednisolone in patients undergoing cardiopulmonary bypass. Pharmacotherapy 10:29-34 (1990).
27. W. Krzyzanski, A. Chakraborty, and W. J. Jusko. Algorithm for application of Fourier analysis for biorhythmic baselines of pharmacodynamic indirect response models. Chronobiol. Int. 17:77-93 (2000).
28. P. T. Kovanen. Regulation of plasma cholesterol by hepatic low-density lipoprotein receptors. Am. Heart J. 113:464-469 (1987).
29. E. J. Antal, C. E. Wright, 3rd, W. R. Gillespie, and K. S. Albert. Influence of route of administration on the pharmacokinetics of methylprednisolone. J. Pharmacokinet Biopharm. 11:561-576 (1983).
30. M. N. Samtani and W. J. Jusko. Comparison of dexamethasone pharmacokinetics in female rats after intravenous and intramuscular administration. Biopharm. Drug Dispos. 26:85-91 (2005).
31. R. Ramakrishnan, D. C. DuBois, R. R. Almon, N. A. Pyszczynski, and W. J. Jusko. Fifth-generation model for corticosteroid pharmacodynamics: application to steady-state receptor down-regulation and enzyme induction patterns during seven-day continuous infusion of methylprednisolone in rats. J. Pharmacokinet. Pharmacodyn. 29:1-24 (2002).
32. Y. N. Sun, D. C. DuBois, R. R. Almon, N. A. Pyszczynski, and W. J. Jusko. Dose-dependence and repeated-dose studies for receptor/gene-mediated pharmacodynamics of methylprednisolone on glucocorticoid receptor down-regulation and tyrosine aminotransferase induction in rat liver. J. Pharmacokinet. Biopharm. 26:619-648 (1998).
33. M. Dobiasova. [AIP-atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice]. Vnitrni Lekarstvi 52:64-71 (2006).
34. T. Vaskonen, E. Mervaala, L. Krogerus, and H. Karppanen. Supplementation of plant sterols and minerals benefits obese Zucker rats fed an atherogenic diet. J. Nutr. 132:231-237 (2002).
35. J. H. Exton. Regulation of gluconeogenesis by glucocorticoids. Monogr. Endocrinol. 12:535-546 (1979).
36. E. Savontaus, I. M. Conwell, and S. L. Wardlaw. Effects of adrenalectomy on AGRP, POMC, NPY and CART gene expression in the basal hypothalamus of fed and fasted rats. Brain Res. 958:130-138 (2002).
37. S. Balasubramaniam, A. Szanto, and P. D. Roach. Circadian rhythm in hepatic low-density-lipoprotein (LDL)-receptor expression and plasma LDL levels. Biochem. J. 298:39-43 (1994).
38. C. Galman, B. Angelin, and M. Rudling. Prolonged stimulation of the adrenals by corticotropin suppresses hepatic low-density lipoprotein and high-density lipoprotein receptors and increases plasma cholesterol. Endocrinology 143:1809-1816 (2002).
39. C. Cabot, A. Salas, R. Ferrer-Lorente, P. Savall, X. Remesar, J. A. Fernandez-Lopez, M. Esteve, and M. Alemany. Short-term oral oleoyl-estrone treatment increases plasma cholesterol turnover in the rat. Int. J. Obes. (Lond) 29:534-539 (2005).
40. T. E. Carew, R. C. Pittman, and D. Steinberg. Tissue sites of degradation of native and reductively methylated [14C]sucrose-labeled low density lipoprotein in rats. Contribution of receptor-dependent and receptor-independent pathways. J. Biol. Chem. 257:8001-8008 (1982).
41. P. Barter, J. Kastelein, A. Nunn, R. Hobbs, and Future Forum Editorial Board. High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis 168:195-211 (2003).
42. R. J. Jennings, N. Lawson, R. Fears, and D. N. Brindley. Stimulation of the activities of phosphatidate phosphohydrolase and tyrosine aminotransferase in rat hepatocytes by glucocorticoids. FEBS Lett. 133:119-122 (1981).